Biodesix Q2 total revenue $11.9M (+180%), core lung diagnostics $4.8M (+109%); NGS test launch accelerated to Q1 2022

BIODESIX INC

Total revenue $11.9M (+180% YoY); core lung diagnostic revenue $4.8M (+109%).
COVID-19 testing revenue $6.1M (+345%) but declining sequentially; net loss $11.4M (+38%).
Gross profit $4.8M (40% margin); operating expenses $15.4M (+93%) due to sales force buildout.
Nodify XL2 milestone triggers $37M obligation payable over six quarterly installments starting Jan 2022.
Accelerated launch of 72-hour liquid NGS test to Q1 2022; cash $56.3M; expects $3.1M PPP loan forgiveness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.